pH of sentinel lymph nodes has correlation with their cancer involvement probability, A human model observational study in breast cancer patients

Supplementary Table 1. Specifications of various metastatic cancerous cells detection methods in the lymph node									
Method	Mechanism	Gold	Declared	Detection	# of Tested				
[Ref.]		Standard	Accuracy	time	Samples				
NC:	Each specimen was placed in a specially	normonant		15–30 min	27 axillary LNs				
Microwave	designed sample holder and scanned using a	permanent H&E stained	-	after wave					
detection of	broadband microwave vector network			ablation	and seven pure cancer tissues				
metastasized breast	analyzer (VNA: HP8510C). In order to	pathology, cytokeratin		ablation	were obtained				
cancer cells in the	measure the permittivity of the area	immunostain			from 12 patients				
lymph node;	corresponding to the size of a hole, a probe	ing			diagnosed with				
potential application	was inserted into each hole of the sample	ing			invasive breast				
for sentinel	holder until the probe tip was securely				carcinoma				
lymphadenectomy	pressed against the sample surface. Then,				curcinoniu				
[1]	using microwave waves (with a bandwidth								
L*J	of up to 30 GHz), cancerous cells in the								
	lymph node were detected.								
Electrical	impedance imaging techniques	permanent	-	5–10 min	three ex vivo				
impedance		H&E stained			human prostates,				
scanning: a new		pathology			ex vivo porcine				
technique in the									
diagnosis of lymph									
nodes in which									
malignancy is									
suspected on Ultrasound									
[2]				1.4					
Real-time in vivo	diffuse reflectance spectroscopy (DRS)	permanent	-	real-time,	ex vivo and in				
tissue		H&E stained		biocompatible	vivo tests of 6				
characterization		pathology			patients				
with diffuse									
reflectance									
spectroscopy									
during									
transthoracic lung									
biopsy: a clinical									
feasibility study									
[3]									
L- J									
The correlation of in	Electromagnetic (EM) breast imaging	permanent	-	low-cost, safe	ex vivo and in				
vivo and ex vivo	······································	H&E stained		and	vivo tests of 21				
tissue dielectric		pathology		potentially	patients				
properties to		1 07		a more	*				
validate				specific					
				modality for					
electromagnetic				cancer					
breast imaging:				detection					
initial clinical									
experience									
[4]									

Supplementary Table 1. Specifications of various metastatic cancerous cells detection methods in the lymph node

BGP	Electrochemical measurement of H2O2	permanent	95%	Additive	In vitro (cell
2.01	release as a byproduct in hypoxia glycolysis	H&E stained	sensitivity	ability of	lines) and In-vivo
	reaction activated in tumor cells with CNT	pathology	5	guiding the	animal models
	covered electrodes	1 00	93%	interventional	with 4T1 and
			accuracy	radiologist to	MC4L2 tumors
			-	remove	
				minimal	
				number of	
				samples under	
				CNB,	
				Evaluate the	
				therapeutic	
				effects on	
				cancer tumors	
				after	
				chemo/radio	
				therapies	
				without	
				complicated	
				and expensive	
				scanning,	
				Simple	
				handheld	
				probe,	
				Precise, real	
				time and fast	
				response	

Supplementary Table 2. Basic information detailed of patients included in the study cohort

Patient	age	Cancer type	Biopsy	Grade	Node	Nodular	Hormone	Treatment
ID			Treatment		Size	states	status	
1	47	IDC	ALND	II	3.5cm	N1	ER+	Adj
							PR+	
							HER2+	
2	30	IDC	ALND	III	7cm	N1	ER+	Adj
							PR+	
							HER2-	
3	41	IDC	ALND	Ι	4cm	N1	ER+	Adj
							PR+	
							HER2+	
4	40	IDC	SLN	Ι	2cm	NO	ER+	Adj
							PR+	
							HER2-	
5	54	IDC	ALND	III	4cm	N1	ER+	Adj
							PR+	
							HER2-	
6	50	IDC	ALND	II	3cm	N2	ER+	Neo
							PR+	
							HER2-	
7	42	IDC	SLN	Ι	2cm	N0	ER+	Adj
							PR+	
							HER2-	
8	45	IDC	ALND	II	4cm	N1	ER-	Adj
							PR-	
							HER2-	
9	47	IDC	SLN	II	3cm	N0	ER+	Adj
							PR+	
							HER2-	

10	41	IDC	ALND	III	4cm	N2	ER+	Neo
10	71	ibe	ALIND		-cili	142	PR+	1100
							HER2-	
11	46	DCIS	SLN	Ι	7cm	N0	ER+	Adj
							PR+	Ū.
							HER2-	
12	27	IDC	ALND	III	4.5cm	N1	ER+	Adj
							PR+	
10	<i>c</i> 0						HER2-	
13	60	IDC	ALND	II	2cm	N1	ER+	Adj
							PR+ HER2+	
14	62	IDC	SLN	Ι	1.5cm	N0	ER+	
14	02	IDC	SLIN	1	1.5011	INU	PR-	_
							HER2-	
15	43	IDC	SLN	Ι	5cm	N0	ER+	Adj
				_			PR+	j
							HER2+	
16	69	IDC	ALND	II	3cm	N1	ER-	Adj
							PR-	
							HER2-	
17	67	IDC	ALND	II	3.5cm	N2	ER+	Neo
							PR+	
10	50	IDC	CL NI	т	2.5	NO	HER2+	A 1'
18	58	IDC	SLN	II	3.5cm	N0	ER+ PR+	Adj
							HER2-	
19	47	IDC	ALND	Ι	3.5cm	N1	ER+	Adj
17	.,	ibe			5.5011	111	PR+	riaj
							HER2-	
20	45	IDC	ALND	II	5cm	N2	ER+	Neo
							PR+	
					_		HER2+	
21	60	IDC+DCIS	SLN	II	1.3cm	N0	ER+	Adj
							PR+	
22	40	60%IDC+invasive	SLN	II	1.2cm	N2	HER2+ ER+	A .d:
LL	40		SLIN	11	1.2011	INZ	PR+	Adj
		micropapillary carcinoma					HER2-	
23	39	IDC	ALND	III	1.4cm	N1	ER+	Adj
							PR+	j
							HER2-	
24	47	IDC	SLN	Ι	0.8cm	N0	ER+	Adj
							PR+	
							HER2-	
25	36	IDC	ALND	II	0.7cm	N0	ER+	Neo
							PR-	
25	40	IDC		т	0.6	NO	HER2+	A 1'
26	49	IDC	ALND	Ι	0.6cm	N0	ER+	Adj
							PR+ HER2-	
27	44	IDC	ALND	Ι	0.8cm	N2	ER+	Adj
21		inc			0.0011	112	PR+	<i>i</i> ng

28	42	IDC	ALND	III	0.4cm	N0	ER+ PR+ HER2-	Neo
29	40	IDC	ALND	II	1.2cm	N3	ER+ PR+ HER2-	Adj
30	34	IDC	ALND	II	1cm	N2	ER+ PR+ HER2-	Adj
31	40	IDC	SLN	II	2cm	N0	ER+ PR+ HER2-	Adj
32	50	IDC+DCIS	SLN	II	1.5cm	N0	ER+ PR+ HER2-	Adj
33	44	IDC	ALND	II	1.5cm	N2	ER+ PR+ HER2-	Adj
34	37	IDC	ALND	II	1cm	N0	ER+ PR+ HER2+	Adj
35	30	IDC	SLN	Ι	1.5cm	N0	ER- PR- HER2-	Adj
36	31	IDC	ALND	II	5cm	N2	ER- PR- HER2-	Neo
37	35	IDC	SLN	II	5cm	N0	ER+ PR+ HER2-	Adj
38	40	IDC	SLN	Ι	2.5cm	N0	ER+ PR+ HER2-	Adj
39	30	IDC	SLN	II	2.5cm	N0	ER+ PR+ HER2-	Adj
40	52	IDC	SLN	Ι	1cm	N0	ER+ PR+ HER2-	Adj

Supplementary Table 3. Lymph node pH evaluations system scoring on lymph node samples vs. pathological diagnoses of 19 breast cancer patients. Positive samples indicated with Red (+), negative samples indicated with green (-). During this test two samples assumed as MLD false (Ten false positive and two false negative: patient's ID 1,2,5,10,14,21,25,38(sample ID 1,5,7,13,21,25,32,40,66,67) and 13, 30 (sample ID 24), 50). This test individually repeated by three needles and if even one of the needles showed acidic pH with pH lower than 7 (as experimentally was calibrated), then the LN would be declared as involved LNs.

Patient ID #	Patient samples #	Type of lymph node	Lymph node pH evaluations system diagnosis (pH value)	Permanent pathology diagnosis		Sensor response compare to Permanent pathology (gold standard)
1	1	Sentinel 1	7	-		FP
1	2	Sentinel 2	7	+		TP
2	3	Sentinel	6	+		TP
2	4	Auxiliary	6	+		TP
		1				

2	5	Auxiliary	6		FP
_	5	2	U	-	**
2	6	Auxiliary 3	6	+	TP
2	7	Auxiliary 4	6	-	FP
2	8	Auxiliary 5	6	+	TP
2	9	Auxiliary 6	6	+	TP
3	10	Sentinel 1	11	-	TN
3	11	Sentinel 2	8	-	TN
4 5	12	Sentinel	8	-	TN
6	13 14	Sentinel 1	<u>6</u> 7	-	FP TP
6	14	Sentinel 1 Sentinel 2	6	++	TP
7	15	Sentinel 2	9	- T	TN
8	10	Sentinel	8	-	TN
9	18	Sentinel 1	8	_	TN
9	19	Sentinel 2	8	-	TN
10	20	Sentinel 1	6	+	TP
10	21	Sentinel 2	7	-	FP
11	22	Sentinel	8	-	TN
12	23	Sentinel	7	+	ТР
13	24	Sentinel	8	+	FN
14	25	Sentinel	7	-	FP
15	26	Sentinel	8	-	TN
16	27	Sentinel	6	+	TP
17	28	Sentinel	7	+	ТР
18	29	Sentinel	6	+	TP
19	30	Sentinel	6	+	TP
20 21	31 32	Sentinel	8 7	-	TN
21	32	Sentinel 1	7.5	-	FP TN
21 22	33	Sentinel 2 Sentinel 1	8	-	TN
22	35	Sentinel 2	7.5	-	TN
23	36	Auxiliary1	8	_	TN
23	37	Auxiliary2	8	-	TN
23	38	Auxiliary3	7.5	-	TN
24	39	Sentinel	8	-	TN
25	40	Auxiliary1	6	-	FP
25	41	Auxiliary2	8	-	TN
26	42	Auxiliary	9	-	TN
27	43	Auxiliary	8	-	TN
28	44	Auxiliary	9	-	TN
29	45	Auxiliary1	6	+	TP
29 29	46 47	Auxiliary2	6.5	+	TP TP
30	47	Auxiliary3 Auxiliary1	6 7	++	TP TP
30	48	Auxiliary1 Auxiliary2	7.5	+	TN
30	50	Auxiliary2	7.5	+	FN
31	51	Sentinel	9	т -	TN
32	52	Sentinel	10	-	TN
33	53	Auxiliary1	10	-	TN
33	54	Auxiliary2	7	+	TP
33	55	Auxiliary3	6.5	+	TP
34	56	Auxiliary	8	-	TN
•	•				

35	57	Sentinel1	8	-	TN
35	58	Sentinel2	8	-	TN
35	59	Sentinel3	8	-	TN
36	60	Auxiliary	۵	+	TP
*1	٦١	Auxiliary ۲	٥	+	TP
٣٦	٦٢	Auxiliary r	0	+	TP
۳۷	٦٣	Sentinel	٨	-	TN
٣٧	٦٤	Sentinel ⁷	٨	-	TN
٣٧	٦٥	Sentinel ^w	٨	-	TN
۳۸	11	Sentinel	٧	-	FP
۳۸	٦٧	Sentinel	٧	-	FP
۳۹	٦٨	Sentinel	٨	-	TN
۳۹	٦٩	Sentinel	٨	-	TN
۳۹	٧.	Sentinel	٨	-	TN
٤.	۷١	Sentinel	٩	-	TN
٤.	۲۷	Sentinel	٩	-	TN
٤.	۷۳	Sentinel	٩	-	TN
٤.	٧٤	Sentinel [£]	٩	-	TN